Download the unmet need in

THE UNMET NEED IN
O VA R I A N C ANCE R
THE PREVALENCE AND CHALLENGES OF OVARIAN CANCER
Early symptoms are non-specific
and difficult to detect:iv,v
Bloating
Pelvic/Abdominal pain
Difficulty
eating
Urinary issues
Ovarian cancer is the
FIFTH MOST DEADLY
cancer in womeni,ii
61% of women with ovarian cancer
are diagnosed in an advanced stage,v
when prognosis is poor
~22,000 new cases will be diagnosed in 2016 in the U.S.iii
~65,000 new cases were diagnosed in Europe in 2012ii
Despite the unmet need, there have been few
new treatment options introduced for patients
with ovarian cancer over the past several decades.
I
POSI
TIVE RE
SP
ON
SE
Even though
most patients with
high-grade serous
ovarian cancer respond
well to standard
therapy...
Platinum-Based
Chemotherapy
TR
T
NI
L
IA
RE
CUR
RENCE RA
TE
For
~85%
E AT M E N T
of patients,
the disease will
RECUR
vi
Up to ~80% of women living with ovarian cancer are afraid of
recurrence.vii,viii
Most women who recur are treated with chemotherapy
and then undergo “watchful waiting”
which can lead to anxiety and uncertaintyix,x
But each round of chemotherapy leads to diminishing
effectiveness and a sobering reality...
Cumulative
toxicities increasexii
Platinum-based
chemotherapy
becomes less
effectivexi
Progression-free
survival becomes
shorterxi
Together, as a community, we are working
towards fulfilling the unmet needs of
women with ovarian cancer, including earlier
diagnosis, reducing recurrence rates and
extending the time between treatments.
LEARN MORE ABOUT TESARO'S
COMMITMENT TO OVARIAN CANCER AT
TES AR O BI O . C O M
i.
ii.
iii.
iv.
v.
Siegel, R., J. Ma, Z Zou, and A Jemal. 2014. “Cancer Statistics, 2014.” CA: A Cancer Journal for Clinicians 64 (1): 9–29. doi:10.3322/caac.21208.
WHO, IARC GLOBOCAN, Cancer Incidence and Mortality Worldwide in 2008 at http://globocan.iarc.fr/. Last Accessed September 28, 2016.
National Cancer Institute. 2016. “Cancer of the Ovary - SEER Stat Fact Sheets.” http://seer.cancer.gov/statfacts/html/ovary.html. Last Accessed June 23, 2016.
American Cancer Society. 2014. “Signs and Symptoms of Ovarian Cancer.” http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Last Accessed Septmber 28, 2016.
American Cancer Society. 2015. Cancer Facts & Figures 2015. Atlanta: American Cancer Society. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/. Last Accessed June 23, 2016.
vi. Birrer, M., and K. Fujiwara. 2016. “Medical Treatment for Relapsed Epithelial Ovarian, Fallopian Tubal, or Peritoneal Cancer: Platinum-Resistant Disease.” UpToDate. http://www.uptodate.com/contents/medical-treatment-for-relapsed-epithelial-ovarian-fallopian-tubal-or-peritoneal-cancer-platinum-resistant-disease. Last Accessed June 23, 2016.
vii. Mirabeau-Beale KL, Kornblith AB, Penson RT, et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecologic Oncology. 2009;114(2):353-359.
viii. Cesario SK, Nelson LS, Broxson A, et al. Sword of Damocles cutting through the life stages of women with ovarian cancer. Oncol Nurs Forum. 2010 Sep; 37(5): 609–617.
ix. Ferrell B, Smith SL, Cullinane CA, Melancon C. Psychological well being and quality of life in ovarian cancer survivors. Cancer. 2003;98(5):1061-1071.
x. Reb AM. Transforming the death sentence: elements of hope in women with advanced ovarian cancer. Oncology Nursing Forum. 2007;34(6):E70-E81.
xi. Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605-2612.
xii. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study.
Gynecologic Oncology. 2006;102(3):432-439.
TESARO, Inc. | 1000 Winter Street | Waltham, MA 02451
TESARO Bio GmbH | Poststrasse 6, 6300 | Zug, Switzerland
TESARO and the logo design presented in this material are trademarks of TESARO, Inc.
©2016 TESARO, Inc. All rights reserved. US.NR.CC.06160081b